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Edited by Ivan SadowskiAbstract Erythroid Kru¨ppel-like factor (EKLF/KLF1) is an
erythroid speciﬁc, C2H2 zinc ﬁnger transcription factor that is
essential for the proper chromatin structure and expression of
the adult b-globin gene. Herein, we determine that 26S protea-
some inhibitors lead to an accumulation of EKLF protein in mur-
ine erythroleukemia (MEL) cells. In addition, EKLF half-life in
both MEL cells (<3 h) and fetal liver cells (between 6 and 9 h) is
stabilized in the presence of these inhibitors. EKLF is ubiquiti-
nated in vivo, however its modiﬁcation does not rely on a partic-
ular internal lysine. Finally, EKLF contains two PEST
sequences within its N-terminus that have no eﬀect on the ability
of EKLF to be ubiquitinated but contribute to its destabilization.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ubiquitin-mediated proteasome system is responsible for
the turnover of proteins within the cell. This degradation sys-
tem plays a vital role in regulating proteins involved in various
cell processes that include cell cycle progression, signal trans-
duction and transcriptional regulation (reviewed in [1,2]). Pro-
teins degraded through this pathway are covalently modiﬁed
with a small, highly conserved, 76 amino acid residue protein
named ubiquitin. Once the protein substrate has been ubiqui-
tinated, polymers of ubiquitin chains may form. These poly-
mers serve as signals that are recognized by the 26S
proteasome for its destruction in an ATP-dependent manner
(reviewed in [3]).
The erythroid Kru¨ppel-like factor (EKLF/KLF1) gene was
isolated in an attempt to discover genes involved in deter-
mining erythroid cell identity [4]. A red-cell speciﬁc transcrip-
tion factor, EKLF contains a DNA binding domain located
at its C-terminus which is composed of three Kru¨ppel-like
C2H2 zinc ﬁnger motifs [4,5] and a proline-rich transactiva-
tion domain at its N-terminus [4]. EKLF preferentially binds
and activates the CACCC site located in the adult b-globin
promoter [4–6]. Mice homozygous null for EKLF die at
E14.5–E15 at the time of hemoglobin switching due to a se-*Corresponding author. Fax: +1 212 860 9279.
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doi:10.1016/j.febslet.2006.03.039vere decrease in b-globin expression [7,8]. Post-translational
modiﬁcations of EKLF regulate its function to achieve var-
ious biological ends. EKLF is phosphorylated in vivo and
this enhances its transactivation function, perhaps by modi-
fying EKLF interaction with a positive acting factor for
transcription [9]. In addition, EKLF is acetylated in vivo
by p300/CBP. This modiﬁcation increases EKLF’s aﬃnity
for the SWI/SNF components of chromatin remodeling com-
plexes which keep chromatin in an open conﬁguration [10–
13]. This latter molecular function may serve to explain
why in the absence of EKLF, not only is there a loss of
b-globin transcription but there is also the loss of correct
chromatin structure at the gene promoter [14]. EKLF also
can interact with the corepressor mSin3A and recruit histone
deacteylases to promoters to inhibit gene transcription and
this interaction is potentially dependent upon EKLF acetyla-
tion status [15,16].
Since the discovery of EKLF/KLF1, a family of Kru¨ppel-
related transcription factors (KLFs) has been described.
These proteins each possess three highly conserved C-termi-
nal C2H2 zinc ﬁngers that serve as a DNA binding domain
yet contain distinct transcriptional domains at their N-termi-
nus [17,18]. Within this family, a subfamily of KLF factors
exists which consists of EKLF, LKLF/KLF2 and GKLF/
KLF4 based on the additional conservation of a 5 0 basic re-
gion just N-terminal to the zinc ﬁnger DNA binding domain.
This region serves as a nuclear localization signal in both
EKLF and GKLF [19,20]. Recently, LKLF/KLF2 has been
identiﬁed to associate with the E3 ligase, WWP1, which pro-
motes its ubiquitination and proteasomal degradation in vivo
[21,22].
Little is known about EKLF protein turnover in the cell
and the mechanism thereof. We sought to identify basic ele-
ments of EKLF proteolysis, speciﬁcally how EKLF protein
levels may be regulated. Here, we discover that inhibition
of the 26S proteasome can aﬀect EKLF protein levels and ex-
tend its half-life in both cultured and primary cells. We also
demonstrate that EKLF is a substrate for ubiquitination
in vivo.2. Materials and methods
2.1. Chemicals
MG132, ALLN, ALLM, calpeptin (all purchased from Calbio-
chem), epoxomicin (Boston Biochem), and cycloheximide (Sigma)
were dissolved in dimethyl sulfoxide (DMSO). Ammonium chloride
and chloroquine (Sigma) were dissolved in water.blished by Elsevier B.V. All rights reserved.
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MEL 745A, 293T and Cos7 cells were maintained in Dulbecco’s
Modiﬁed Enriched Medium (DMEM) (Mediatech, Inc.) supplemented
with 10% FBS. All cells were cultured in a humidiﬁed incubator at
37 C in a 5% CO2 air atmosphere.
2.3. Cell extract preparation
Extracts were prepared as previously described with a few modiﬁca-
tions [15]. Pellets collected from actively growing cells were resus-
pended in 3· the volume of the cell pellet of NE-A buﬀer. Finally,
extracts were centrifuged at 45000 rpm for 15 min at 4 C on a
S45A-0230 rotor (Sorvall microultracentrifuge M150 model).
2.4. Western blot analysis
Protein concentration was determined with Bradford protein assay
(Bio-Rad) according to the manufacturer’s protocol using bovine
serum albumin (BSA) as the standard. Equal protein concentrations
as determined by Bradford Assay were subjected to SDS–PAGE gel
electrophoresis and electroblotted onto nitrocellulose. Membranes
were probed with the following primary antibodies: anti-EKLFEKLF 
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Fig. 1. Various proteasome inhibitors aﬀect EKLF protein levels. (A) MEL
(0.4% v/v). Whole cell extracts were prepared and 30 lg of total protein was
Western blot for EKLF. ERK served as the protein loading control. The fold
to ERK loading control. The results are the average of two independent expe
for 3 h with 20 lM MG132 or DMSO vehicle control and from fetal liver
expression. Messenger RNA was reverse transcribed into cDNA and ampl
EKLF or HPRT in the presence of a radiolabeled tracer. EKLF levels were n
concentrations of epoxomicin (0.1–100 lM), lactacystin (1–100 lM) or DM
prepared and evaluated via Western blot using an anti-EKLF antibody. ERK
for epoxomicin and lactacystin activity. The fold eﬀects of the proteasome i
ERK loading control. The results are the average of up to three independenpolyclonal antibody [23], anti-ERK 1 monoclonal antibody (BD
Biosciences, Transduction Laboratories), anti-p21 monoclonal anti-
body (F-5; Santa Cruz), anti-GFP monoclonal antibody (JL-8;
Clontech), or anti- HA (12CA5) antibody (Mount Sinai Hybridoma
Center). Membranes were then probed with one of the following
secondary antibodies: anti-rabbit conjugated to horseradish peroxi-
dase (HRP) (Jackson Labs), or anti-mouse conjugated to HRP
(Pierce). Chemiluminescent detection (Pierce) was utilized. For
immunoblot of Flag-tagged EKLF and EKLF variants, membranes
were probed with anti-Flag M2 antibody conjugated to HRP
(A8592; Sigma). EKLF typically migrates as a doublet under these
conditions [23]. A slower migrating band (e.g. Figs. 1 and 2) is
non-speciﬁc.
Where indicated, the resulting bands were quantitated using the
NIH Image 1.62 program. For endogenous protein expression, EKLF
signals were normalized to ERK loading control to obtain the fold ef-
fects or relative EKLF levels. When transiently expressed, the EKLF
expression level of each sample was normalized to the expression level
of the GFP transfection control. In all cases, the relative EKLF protein
levels were quantitated by dividing each sample in the set by the 0 h
timepoint quantity.MEL 
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loaded in each lane. Extracts were analyzed via 12% SDS–PAGE and
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riments. (B) RNA was isolated from untreated MEL cells, cells treated
cells from day 13.5 embryos to serve as a positive control for EKLF
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ormalized to HPRT. (C) MEL cells were treated for 6 h with increasing
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Fig. 2. Proteasome inhibitors stabilize EKLF protein levels in both
MEL and primary fetal liver cells. Total cell extracts were prepared
and 30 lg protein was loaded in each lane and evaluated via a 12%
SDS–PAGE gel and Western blot for EKLF. ERK served as the
protein loading control. (A) MEL cells were treated with cyclohexi-
mide (100 lg/ml) and MG132 (20 lM) or DMSO vehicle control (0.5%
v/v) for 0–9 h. (B) MEL cells were treated with cycloheximide (100 lg/
ml) and epoxomicin (10 lM) or DMSO vehicle control (0.2% v/v) for
0–12 h. (C) Fetal liver cells were isolated from 13.5 day embryos and
cultured as in (A) for 0, 3, 6, 9 and 23 h. Relative EKLF protein levels
present at the various cycloheximide timepoints were quantitated after
EKLF levels were normalized to ERK loading control. 0 h served as
the starting point with a ratio of 1 and relative levels of EKLF over
time were determined. The results are the average of two independent
experiments.
K.J. Quadrini, J.J. Bieker / FEBS Letters 580 (2006) 2285–2293 22872.5. Plasmid constructs
A Flag tag was inserted into the pSG5-EKLF construct at the ami-
no-terminus of EKLF [4]. The CMVhemagglutinin (HA)-tagged ubiq-
uitin expression plasmid was the kind gift of Zhen-qiang Pan. The
pEGFP-C1 mammalian expression vector (Clontech) was as described
[19].
The QuikChange Mutagenesis kit (Stratagene) was utilized to gener-
ate the various EKLF mutants according to the manufacturer’s proto-
col. The pSG5-Flag-EKLF construct served as the template for these
reactions. All clones were sequenced for incorporation of the appropri-
ate mutation or deletion. All primer sequences are available upon
request.2.6. Cell transfections
Transfection of 293T cells was performed using FuGENE 6 reagent
(Roche Molecular Biochemicals) according to the manufacturer’s pro-
tocol. pSG5-Flag-EKLF and/or HA-tagged ubiquitin expression plas-
mids were transfected at a 1:1 ratio. Empty pSG5 vector was utilized to
keep the transfected DNA concentration constant when necessary [4].
The total transfected DNA concentration equaled 5.6 lg. Transfection
of Cos7 cells was performed using the DMRIE lipofection method
(Invitrogen).
2.7. In vivo ubiquitination assay
40-48 h post-transfection, cells were harvested with PBS containing
10 mM N-ethylmaleimide (NEM) (Sigma) and 200 lM iodoacetamide
(Fluka, Biochemika). Cells were washed with PBS, centrifuged and
subjected to one freeze–thaw cycle. Cell pellets were then resuspended
in 200 ll RSB (10 mM Tris–HCl, pH 7.5, 10 mM NaCl, 0.5% NP-40,
5 mM EDTA, 5 mM EGTA plus 20 mM NEM, 200 lM iodoaceta-
mide, 6.8 lg/ml PMSF, 10 lg/ml leupeptin, 5 mM sodium ﬂuoride,
1 mM sodium vanadate and 1 complete EDTA-free cocktail tablet
(Roche Molecular Biochemicals)) and sonicated in a water bath
(UltrasonicProcessor XL, Heat Systems) for 20 s pulse-10 s rest for
6 min. 500 ll LSB (20 mM Tris–HCl, pH 7.5, 1 M NaCl, 0.5% NP-
40, 5 mM EDTA, 5 mM EGTA plus 20 mM NEM, 200 lM iodoacet-
amide, 6.8 lg/mlPMSF, 10 lg/ml leupeptin, 5 mM sodium ﬂuoride,
1 mM sodium vanadate and 1 complete EDTA-freecocktail tablet
(Roche Molecular Biochemicals)) was added per pellet and extracts
were subjected to one hour rotation at 4 C. Extracts were then centri-
fuged at 45 Krpm for 30 min on a S45A-0230 rotor (Sorvall micro-
ultracentrifuge M150 model). Total protein concentration in extracts
was quantitated using the Bradford protein assay solution (Bio-
Rad). Equal protein amounts were incubated with 40 ll anti-Flag
M2 conjugated agarose beads (A2220; Sigma) that were prewashed
two times with PBS containing 10 mM NEM and 200 lM iodoaceta-
mide and then two times with 1:1 RSB:LSB. Immunoprecipitation
was conducted for 2 h at 4 C, rotating. The beads were then washed
three times with 1:1 RSB:LSB, resuspended in 40 ll of two times
SDS loading buﬀer and heated at 95 C. Equal volume of each sample
was loaded onto 10% SDS–PAGE gels. Western blots were performed
as described above.
2.8. E13.5 Fetal liver extracts
Fetal livers were dissected from day 13.5 embryos into cold PBS con-
taining 50 U/ml Heparin (Sigma). Cells were incubated for various
timepoints in DMEM plus 25 ng/ml Stem Cell Factor (R&D Systems)
and 2 U/ml Erythropoietin (Amgen, Inc.) [24] in the presence of cyclo-
heximide (100 lg/ml) plus either DMSO or 20 lM MG132.
2.9. RNA isolation, cDNA synthesis and semiquantitative PCR
RNA analysis was conducted as previously described [25]. RNA
from 1 · 106 untreated MEL cells, cells treated with 20 lM MG132
or DMSO vehicle control for 3 h or RNA from E13.5 fetal liver cells
was isolated after homogenization. For semiquantitative PCR, cDNA
from each sample using the Sensiscript Reverse Transcriptase kit (Qia-
gen) was utilized as template in conjunction with Taq DNA Polymer-
ase (Qiagen), [32P]dCTP as radiolabeled tracer and primers as
previously described [23]. Samples were resolved on a 5% polyacryl-
amide gel, after which the dried gel was exposed to ﬁlm (Kodak
XAR) for autoradiography.3. Results
3.1. EKLF levels increase in response to proteasome inhibition
To determine whether there was a role for proteolysis in reg-
ulating EKLF steady-state protein levels in erythroid cells, var-
ious inhibitors were utilized to aﬀect cellular proteolysis.
Addition of a concentration of the peptide aldehyde inhibitor,
MG132 (20 lM), that did not appreciably aﬀect cell viability
(data not shown) caused slight but reproducible accumulation
of EKLF protein levels within 3 h of incubation relative to
those EKLF protein levels present in untreated deﬁnitive
2288 K.J. Quadrini, J.J. Bieker / FEBS Letters 580 (2006) 2285–2293erythroid murine erythroleukemia (MEL) cells (Fig. 1A). This
was concurrent with a slight reduction of EKLF mRNA levels
in the MG132 treated cells (Fig. 1B). Treatment of MEL cells
with DMSO vehicle control had no eﬀect relative to untreated
MEL cells at either the mRNA or protein level (Fig. 1A and
B). Therefore, treatment of MEL cells with proteasome inhib-
itors leads to an accumulation of EKLF protein within cells
through the inhibition of a pathway important for post-trans-
lational degradation of the EKLF protein. Two other peptide
aldehyde inhibitors, ALLN (also known as calpain inhibitor I)
and ALLM (also known as calpain inhibitor II) also increased
EKLF protein levels after three hours of treatment similar to
that in cells treated with MG132 at 3 h (data not shown).
ALLM seemed to show a slight eﬀect after 6 h (data not
shown).
Other cellular pathways of proteolysis exist: calpain-medi-
ated degradation or the lysosomal pathway [26]. Since peptide
aldehydes can also inhibit certain lysosomal acidic cysteine
proteases (cathepsins) as well as the cellular calcium-dependent
calpains [27], we investigated whether inhibitors of lysosomal
function (ammonium chloride or chloroquine) or calpains (cal-
peptin) could aﬀect EKLF proteolysis. They did not cause the
accumulation of EKLF protein over a wide range of concen-
trations (data not shown).
Since peptide aldehydes have been documented to aﬀect
both cellular extra-lysosomal cysteine proteases known as cal-
pains [27–29] and the 26S proteasome, more speciﬁc inhibitors
of the proteasome were also tested to ensure that the protea-
some is the actual agent of proteolysis. Lactacystin [30], an
irreversible inhibitor of the chymotrypsin-like and trypsin-like
activities of the 20 S proteasome catalytic core, was tested at a
concentration suﬃcient to inhibit proteasomal degradation
and cause the accumulation of other substrates in vivo
[31,32]. At a concentration of 10 lM, lactacystin had no eﬀect
on EKLF protein levels in MEL cells when compared to
MG132 treated cells (Fig. 1C, compare lanes 1, 2 with lane
9). At this concentration of lactacystin, there was no apprecia-
ble eﬀect on cell viability for the 6 h incubation time (data not
shown). These results were unexpected since all other protea-
some inhibitors tested had an eﬀect on EKLF protein levels.
However, MEL cells treated with increasing concentrations
of lactacystin in which there was no cytotoxicity shows that
EKLF protein levels are increased when cells are treated with
the highest concentration of lactacystin (100 lM) (Fig. 1C,
lane 11). Cells were also treated with epoxomicin, another spe-
ciﬁc irreversible proteasome inhibitor, at varying concentra-
tions [33]. With the addition of 1 lM epoxomicin, EKLF
protein levels increased in MEL cells equal to levels present
in cells treated with MG132 (Fig. 1C, lane 4). Since epoxomi-
cin has been estimated to be 100· more potent than lactacystin
[33,34], it is not surprising that EKLF levels present in cells
treated with 1 lM epoxomicin are equivalent to that in cells
treated with 100 lM of lactacystin (Fig. 1C). Therefore, highly
speciﬁc inhibitors of the proteasome were suﬃcient to cause an
increase in the steady-state levels of EKLF protein in MEL
cells.3.2. Proteasome inhibitors stabilize EKLF
Cycloheximide causes translational arrest of mRNA in the
cell. Inhibition of de novo protein synthesis enables determina-
tion of the turnover rate of a selected protein. Treatment ofMEL with 100 lg/ml cycloheximide indicates that levels of
EKLF are reduced by approximately 50% within 3 h of treat-
ment. These protein levels can be stabilized to a half-life of
greater than 9 h when cells are simultaneously treated with
the proteasome inhibitor, MG132 (Fig. 2A). Similarly, when
MEL cells are treated with both cycloheximide and epoxomi-
cin, EKLF protein levels can be stabilized to levels that are
equivalent to those present in untreated for a half-life of great-
er than 12 h (Fig. 2B). Since the degradation of EKLF can be
blocked through the use of inhibitors of the proteasome, we
conclude that the predominant pathway through which EKLF
steady-state protein turnover occurs is the 26S proteasome
pathway.
To determine whether the same phenomenon occurs in pri-
mary fetal liver cells where EKLF is expressed in vivo [23], pri-
mary fetal liver cells were isolated from 13.5 day embryos and
cultured in the presence of cycloheximide. In contrast with
EKLF present in MEL cells, EKLF from fetal liver cells did
not decrease to 50% until between 6 and 9 h (Fig. 2C, lanes
4 and 5). When cells were grown in the presence of both cyclo-
heximide and MG132, inhibition of the proteasome stabilized
the EKLF protein population for a half-life of about 23 h
(Fig. 2C, lane 11). While the kinetics of EKLF turnover was
not identical in the two cell populations, EKLF in both
MEL cells and primary fetal liver cells responded similarly to
proteasome inhibition.3.3. EKLF can be ubiquitinated in vivo
Since EKLF protein levels accumulate and are stabilized in
the presence of various proteasome inhibitors, EKLF itself
may serve as a substrate for ubiquitin modiﬁcation. To test
this, Flag-tagged EKLF and HA-tagged ubiquitin were tran-
siently co-expressed in 293T cells and subsequently immuno-
precipitated in the presence of NEM and iodoacetamide,
which inhibit the deubiquitinating isopeptidase enzymes within
the cell [35]. Subsequent immunoblot analysis indicates that
EKLF is ubiquitinated even in the absence of MG132
(Fig. 3A). Similarly, when cells are transfected with EKLF
alone and those extracts are immunoblotted with an EKLF
antibody, there is an increased accumulation of ubiquitin-con-
jugates caused by the covalent attachment of endogenous
ubiquitin to the EKLF protein. The ubiquitin-conjugates that
appear when EKLF is transfected alone are enhanced when
cells were treated with MG132 as compared to DMSO treated
cells (Fig. 3B, upper panel, compare lanes 3 and 6). This was
not due to an increase in unmodiﬁed EKLF protein levels as
the levels are similar in both (Fig. 3C, lower panel, compare
lanes 3 and 6).
Lysines serve as the predominant acceptor sites for covalent
ubiquitin attachment in the substrate protein [1,2]. A particu-
lar lysine can serve as the target for the ubiquitin tag in a
site-speciﬁc manner or a single lysine within EKLF may be
essential for its ubiquitination. Murine EKLF contains a total
of 11 lysines throughout its primary sequence. Five are located
within the proline-rich, transactivation domain (amino acids
19–292) and 6 are located within the zinc ﬁnger DNA binding
domain (amino acids 293–376) (Fig. 4A). Every one of these
lysines is precisely conserved between the mouse and human
EKLF except for two, lysine 74 (K74) and lysine 177
(K177), and these only vary slightly in location, but not in
the conserved sequence (Fig. 4A). Each lysine was individually
Mouse EKLF    MRQKRERRPEVQGGHQPAMASAETVLPSISTLTTLGQFLDTQEDFLKWWRSEETQDLGPG 60
Human EKLF    ------------------MATAETALPSISTLTALGPFPDTQDDFLKWWRSEEAQDMGPG 42
Mouse EKLF    PPNPTGPSLHVSLKSEDPSGEDDERDVTCAWDPDLFLTNFPGSESPGTSRTCALAPSVGP 120
Human EKLF    PPDPTEPPLHVKSEDQPGEEEDDERGADATWDLDLLLTNFSGPEPGGAPQTCALAPSEAS 102
Mouse EKLF    VAQFEPP-ESLGAYAGGPGLVTGPLGSEEHTSWAHPTPRPPAPEPFVAPALAPGLAP--- 176
Human EKLF    GAQYPPPPETLGAYAGGPGLVAGLLGSEDHSGWVRPALRARAPDAFVGPALAPAPAPEPK 162
Mouse EKLF    --KAQPSYSDSRAGSVGGFFPRAGLAVPAAPGAPYGLLSGYPALYPAPQYQGHFQLFRGL 234
Human EKLF    ALALQPVYPGPGAGSSGGYFPRTGLSVPAASGAPYGLLSGYPAMYPAPQYQGHFQLFRGL 222
Mouse EKLF    AAPSAGGTAPPSFLNCLGPGTVATELGATAIAGDAGLSPGTAPPKRSRRTLAPKRQAAHT 294
Human EKLF    QGPAPGPATSPSFLSCLGPGTVGTGLGGTAE--DPGVIAETAPSKRGRRSWARKRQAAHT 280
Mouse EKLF    CGHEGCGKSYSKSSHLKAHLRTHTGEKPYACSWDGCDWRFARSDELTRHYRKHTGHRPFC 354
Human EKLF    CAHPGCGKSYTKSSHLKAHLRTHTGEKPYACTWEGCGWRFARSDELTRHYRKHTGQRPFR 340
Mouse EKLF    CGLCPRAFSRSDHLALHMKRHL 376
Human EKLF    CQLCPRAFSRSDHLALHMKRHL 362
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exposed version of the upper panel. Non-speciﬁc band is denoted with an asterisk (*), and migration of protein molecular weight markers are as
indicated (in kDa).
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protein and these EKLF mutants were tested for their ability
to be ubiquitinated in vivo. As the results demonstrate, not a
single lysine to arginine mutation served to completely abolish
EKLF’s ability to be ubiquitinated (Fig. 4B–D). Both
EKLFK74R and EKLFK177R showed an overall decrease
in ubiquitin-conjugated EKLF intensity but this was not con-
sistently observed. Because of this, it was necessary to examine
if perhaps an EKLF double mutant may exhibit less ubiquiti-
nation implying that these amino acids may be involved in
ubiquitination in some circumstances. However, EKLF mu-
tated at both K74 and K177 displayed levels of ubiquitination
equal to that of wild type EKLF, indicating that this is not
likely the case (see supplemental ﬁgure). EKLF’s two acetyla-
tion sites, K288 and K302 [13] were not eﬀective at eliminating
EKLF ubiquitination (Fig. 4C). Therefore, there may not be a
direct competition between ubiquitination and acetylation in
EKLF. Since a particular lysine is not essential for EKLF
ubiquitination, we suggest that EKLF is not ubiquitinated in
a site-speciﬁc manner, but that either alternate lysines may
serve to receive the modiﬁcation or many acceptor lysines
may serve to receive the modiﬁcation.
3.4. Absence of PEST sequences within EKLF does not aﬀect its
ubiquitination but does alter EKLF half-life in vivo
A variety of signals within the substrate exist to direct ubiq-
uitination of the substrate protein [1]. PEST sequences are
present in many short lived proteins and may serve as potential
signals for their degradation (reviewed in [36,37]). Using a
web-based algorithm, PEST-FIND (https://emb1.bcc.univie.
ac.at/toolbox/pestﬁnd/pestﬁnd-analysis-webtool.htm), EKLF
contains two highly probable PEST sequences. These two sig-
nals are demarcated in Fig. 4A. The ﬁrst, PEST 1, is 21 amino
acids long (amino acids 50–70) and is just C-terminal to the
casein kinase (CK) II consensus site within which a threonine
at amino acid 41 is required for the transactivation capabilities
of the EKLF minimal transactivation domain [9,38]. TheFlag-EKLF
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Fig. 5. Deletion of PEST sequences does not abolish EKLF ubiquitination. 2
with a deletion of PEST 1 and HA-tagged ubiquitin (HA-Ub) expression vec
HA-Ub constructs (B). Equal protein amounts were immunoprecipitated wi
anti-HA and anti-Flag antibodies. Non-speciﬁc band is denoted with an as
indicated (in kDa).second, PEST 2, is 12 amino acid residues long (amino acids
74–85) and is also located within the minimal transactivation
domain of EKLF [38]. Both sites are surrounded with a lysine
which could potentially be ubiquitinated (K47 and K74,
respectively). Both sequences are also relatively highly con-
served with human EKLF (Fig. 4A). To explore if the absence
of a PEST sequence within EKLF aﬀects its ubiquitination
in vivo, each sequence was deleted in the context of the full-
length EKLF protein and ubiquitination assays were per-
formed. Neither deletion of PEST 1 (EKLFDPEST 1)
(Fig. 5A) nor deletion of PEST 2 (EKLFDPEST 2) (Fig. 5B)
could substantially reduce EKLF ubiquitination. We note that
deletion of PEST 1 (EKLFDPEST 1) might cause hyperubiqui-
tination of EKLF (Fig. 5A). It is possible that while this
sequence does not aﬀect EKLF ubiquitination, it may inﬂu-
ence the turnover of the EKLF protein (see Section 4 for
further comment).
While the PEST sequences within EKLF may not aﬀect the
ability of EKLF to be ubiquitinated, they may aﬀect EKLF’s
turnover rate. To test this, full-length EKLF, EKLFDPEST
1 or EKLFDPEST 2 was transiently transfected into Cos7
cells. One day post-transfection, the cells were treated with
100 lg/ml cycloheximide for 0, 3 and 6 h to determine whether
the absence of a PEST sequence could stabilize the EKLF pro-
tein and extend its half-life (Fig. 6A). While there was little to
no eﬀect on the turnover of EKLF after 3 h, by 6 h the absence
of PEST 1 signiﬁcantly rendered EKLF more stable (Fig. 6C).
At the same time, enhanced stability of EKLFDPEST 2 had a
P-value approaching statistical signiﬁcance. We also tested the
mutation of lysine 74 within EKLF and its eﬀect on EKLF
turnover in this assay given its presence within PEST 2
(Fig. 4B). However due to the extent of variation within the
samples, it does not appear that mutation of lysine 74 has a
signiﬁcant eﬀect on EKLF turnover in Cos7 cells (Fig. 6B
and C). Therefore PEST 1, and to a lesser extent PEST 2, with-
in EKLF help destabilize the EKLF protein and their absence
leads to an extension of EKLF half-life within the cell.Flag-EKLF
HA-Ub
lag-EKLFΔPEST 2
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93T cells were transiently transfected with pSG5-Flag-EKLF or EKLF
tors (A) or pSG5-Flag-EKLF or EKLF with a deletion of PEST 2 and
th anti-Flag antibody and subsequent Western blots were probed with
terisk (*), and migration of protein molecular weight markers are as
Fig. 6. Deletion of PEST sequences stabilizes EKLF and extends its half-life. Cos7 cells were transfected with wild type Flag-tagged EKLF or EKLF
deleted of either PEST 1 or PEST 2 (A) or EKLF with lysine 74 mutated to arginine (B). Cells were also transfected with 1/5 total DNA of pEGFP-
C1 which served as a internal control for transfection. 20–24 h post-transfection, cells were incubated with cycloheximide (100 lg/ml) (0.1% v/v) for 0,
3 and 6 h. Total cell lysates were prepared and Western blot was performed using anti-Flag or anti-GFP antibody. (C) Relative EKLF protein levels
between cycloheximide timepoints from (A) and (B) were quantitated after EKLF levels were normalized to internal transfection control GFP
expression levels. 0 h served as the starting point with a ratio of 1 and relative levels of EKLF, EKLFDPEST 1, EKLFDPEST 2 and EKLFK74R
over time were determined. Results are the average of three independent experiments. Standard deviations and P-values for each construct as
determined by unpaired Student’s t-tests are indicated in the graph.
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Our results are the ﬁrst evidence to date that EKLF can be
degraded via the proteasome pathway and that it can be
ubiquitinated in vivo. Many regulatory proteins and tran-
scription factors are regulated through their protein expres-
sion levels. p53 [39], MyoD [40], IjBa [41,42] and c-Myc
[43] are all regulated via the ubiquitin-mediated proteasome
pathway. While the proﬁle and kinetics of EKLF protein lev-
els in MEL versus fetal liver cells are diﬀerent, both popula-
tions of EKLF are susceptible to proteasome inhibition,
further enforcing the role the proteasome may have for
EKLF in the erythroid cell. We suggest that the half-life ki-
netic diﬀerences between cell lines and primary fetal liver
cells when treated with cycloheximide may be due to culture
conditions and result from diﬀerent characteristics of the two
cell populations. Embryonic day 13.5 fetal liver cells are a
mixed population of deﬁnitive erythroid cells at diﬀerent
stages of diﬀerentiation in contrast to the clonal, cultured
MEL cells.Here, we have determined that a single lysine is not essential
for EKLF ubiquitination (Fig. 4). There is no consensus as to
which internal lysine residues are modiﬁed with ubiquitin. In
some cases, speciﬁc lysines are vital within the protein (e.g.
IjBa lysines 21 and 22 [42] and LKLF/KLF2 lysine 121
[22]). In other cases, there is little or no speciﬁcity as to which
lysine within the protein is conjugated (e.g. c-Jun [44] and T-
cell receptor f chain [45]). Based on our studies, we suggest
that EKLF falls into the latter category, where lysine speciﬁc-
ity is not a factor in EKLF ubiquitination.
WWP1, an E3 ligase containing WW domains which recog-
nize proline-rich, phosphoserine and phosphothreonine
stretches, has been recently identiﬁed to attenuate LKLF/
KLF2 transactivation through promoting the downregulation
of LKLF via interaction with its inhibitory domain [21,22]. An
inhibitory domain exists near the zinc ﬁnger domain in EKLF
and GKLF as well [38,46]. The inhibitory domains are similar
in location and function within these proteins but there is no
consistent conservation in the amino acid sequence between
them. Also, no conserved lysines exist outside of those present
2292 K.J. Quadrini, J.J. Bieker / FEBS Letters 580 (2006) 2285–2293within the zinc ﬁnger domain and the adjacent 5 0 basic region
of these proteins. EKLF appears to have no single lysine resi-
due which is site-speciﬁcally ubiquitinated in contrast with
LKLF (at lys-121). KLF2/LKLF also reportedly has a PEST
sequence (amino acids 164–184) which resides within its inhib-
itory domain and is located nearby its speciﬁc ubiquitination
site at lys-121 [22]. In contrast, EKLF contains two PEST se-
quences that are conserved (see Fig. 4A) but not located within
its inhibitory domain. With these signiﬁcant diﬀerences, it is of
no surprise that the WWP1 protein is speciﬁc for LKLF and
does not interact with EKLF [21].
In our studies, the PEST sequences contribute to EKLF deg-
radation. PEST sequences are present in many short-lived pro-
teins and their presence may serve as a signal for
ubiquitination and thus degradation of a protein (reviewed
in [36,37]). While EKLF is still ubiquitinated without either
of its PEST sequences, its turnover is slower. This indicates
that the PEST sequence is not necessary for ubiquitination
but it is for degradation. A similar phenomenon has been ob-
served in the case of c-Myc [43]. It has been suggested that the
negative charge in the PEST sequence may be required for pro-
tein unfolding after docking at the proteasome [47]. Thus,
PEST sequences in EKLF, like that in c-Myc, may play an
important functional role between the ubiquitination and the
subsequent degradation of the protein. Additionally, the pres-
ence of hyperubiquitinated EKLF in the absence of PEST 1
(Fig. 5) is consistent with the data indicating that EKLF is
more stable in its absence (Fig. 6). As proposed in the case
of c-Myc, hyperubiquitination could be the result of the accu-
mulation of ubiquitinated protein that is not degraded [48].
This reinforces that this sequence most likely functions at a
step post-ubiquitination but prior to actual degradation.
In addition to its well characterized activation function,
EKLF has been determined to serve repressor functions in
the cell at individual promoters [15,16] possibly also at the
IL-12 p40 gene promoter [49,50] and may have an antiprolifer-
ative eﬀect on cells [51]. Other KLF factors have been deter-
mined to eﬀect cell growth and diﬀerentiation. Tight control
of EKLF protein levels may be necessary to ensure that only
the appropriate amount is present in the cell at any given time
and this may aﬀect its ability to activate or repress target genes.
In addition, EKLF degradation may be regulated through the
proteasome during diﬀerentiation as general protein levels
within erythroid cells decrease during diﬀerentiation [52].
EKLF mRNA levels do not change with the onset of terminal
diﬀerentiation [4], yet EKLF protein levels in MEL cells de-
crease substantially during HMBA-induced terminal diﬀerenti-
ation while its target gene, b-globin, increases in mRNA and
protein levels ([53] and Quadrini and Bieker, unpublished
observations). Taken together, this implicates a potential
post-translational control mechanism for regulation of EKLF
levels during diﬀerentiation. Given our observations, we sug-
gest that EKLF levels may be regulated via the ubiquitin-med-
iated proteasome pathway during terminal diﬀerentiation of
MEL cells. Another C2H2 zinc ﬁnger transcription factor,
Yin Yang 1 (YY1), also relies on ubiquitin-mediated proteaso-
mal degradation for its downregulation during both skeletal
and cardiac muscle diﬀerentiation [29]. EKLF plays a promi-
nent role during erythroid diﬀerentiation in ensuring the
expression of b-globin. However, if EKLF induces too much
b-globin transcription it would result in an imbalance with
a-globin. It is therefore possible that a mechanism of proteo-lytic activity during diﬀerentiation would exist to ensure feed-
back of b-globin expression, keeping transcription levels at a
correct rate.
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